FDA eases IRB review of COVID-19 expanded access requests

Institutional review boards (IRBs) may establish procedures to have a single IRB member review individual patient expanded access requests for investigational drugs and biologic products to treat coronavirus disease (COVID-19), says new guidance from the US Food and Drug Administration (FDA).